Multiple System Atrophy (MSA) is fundamentally an oligodendrogliopathy — a disease where oligodendrocytes (the myelin-producing cells of the CNS) are the primary pathological target. This distinguishes MSA from Parkinson's disease where neurons are the primary target, and makes glial pathology the central focus for understanding disease mechanisms and developing therapies.
The glial pathology in MSA encompasses three major cell types:
These three cell types interact in a self-reinforcing cycle of dysfunction that drives progressive neurodegeneration[1].
Wenning and colleagues proposed in 2009 that MSA is primarily an oligodendrogliopathy — a disease where the primary pathological target is the oligodendrocyte[2]. Key evidence:
For detailed mechanisms, see MSA Glial Pathologies and Oligodendrocyte Dysfunction.
GCIs are the pathognomonic histological hallmark of MSA, present in over 95% of pathologically confirmed cases[3]. Unlike neuronal Lewy bodies found in Parkinson's disease, GCIs:
For detailed GCI biology, see MSA Alpha-Synuclein Glial Cytoplasmic Inclusions.
Key formation mechanisms[4]:
Alpha-synuclein pathology: Pathological alpha-synuclein with Ser129 phosphorylation accumulates in oligodendrocytes. The source may be neuron-derived exosomes or direct uptake from extracellular space[5].
Metabolic vulnerability: Oligodendrocytes in MSA show specific metabolic defects — impaired mitochondrial function and reduced glycolytic capacity[6].
Myelin dysfunction: Progressive myelin breakdown precedes GCI formation, suggesting oligodendrocyte dysfunction may be the primary event[7].
Impaired proteostasis: Both autophagy-lysosome and ubiquitin-proteasome systems are dysfunctional, preventing clearance of aggregated proteins.
Oligodendrocyte loss in MSA causes progressive myelin breakdown:
| Myelin Component | Change in MSA | Functional Impact |
|---|---|---|
| MBP (Myelin Basic Protein) | Severely reduced | Loss of structural integrity |
| PLP (Proteolipid Protein) | Decreased | Membrane instability |
| MOG (Myelin Oligodendrocyte Glycoprotein) | Decreased | Surface recognition loss |
| CNP (2',3'-Cyclic Nucleotide 3'-Phosphodiesterase) | Decreased | Axonal support impaired |
Regional vulnerability: cerebellar peduncles, pontocerebellar fibers, and basal ganglia white matter.
For more detail, see MSA Oligodendrocyte Pathology.
Astrocytes in MSA undergo significant morphological and functional alterations:
Microglial activation is a prominent feature of MSA pathology:
| Brain Region | Oligodendrocyte | Astrocyte | Microglia | Clinical Correlation |
|---|---|---|---|---|
| Cerebellar white matter | Severe | Moderate | Moderate | Ataxia (MSA-C) |
| Basal ganglia | Severe | Moderate | Severe | Parkinsonism (MSA-P) |
| Brainstem | Moderate | Mild | Moderate | Autonomic dysfunction |
| Spinal cord | Moderate | Mild | Mild | Autonomic failure |
| Cerebral white matter | Mild | Mild | Mild | Cognitive decline |
See also MSA Treatment Approaches and Emerging Therapies.
Pathological alpha-synuclein in MSA exhibits prion-like properties:
Oligodendrocyte precursor cells (OPCs) show proliferation in response to demyelination but fail of differentiation and remyelination in established MSA — a potential therapeutic target.
Jellinger KA, et al. Glial pathology in multiple system atrophy: new insights into pathogenesis. Acta Neuropathologica. 2023. ↩︎
Wenning GK, et al. Multiple system atrophy: a primary oligodendrogliopathy. Annals of Neurology. 2009. ↩︎
Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy. Brain. 1989. ↩︎
Stefanova N, et al. Molecular basis of multiple system atrophy pathophysiology. Acta Neuropathologica. 2022. ↩︎
Singer TP, et al. Alpha-synuclein propagation in oligodendrocytes: implications for MSA. Nature Neuroscience. 2022. ↩︎
Bott C, et al. Metabolic vulnerability of oligodendrocytes in multiple system atrophy. Nature Metabolism. 2024. ↩︎ ↩︎
Yamada S, et al. Myelin dysfunction and oligodendrocyte loss in multiple system atrophy. Brain. 2024. ↩︎
El Andaloussi A, et al. Oligodendroglial exosome-mediated alpha-synuclein transmission in MSA. Cell Reports. 2023. ↩︎